Table 2 Novel vaccine-based immunotherapeutic approaches for PC patients
Type | Interventions | Study name | Condition/disease | Development stage | References or Study number |
|---|---|---|---|---|---|
Bacteria-based cancer vaccine | JNJ-64041809 (ADU-741) | LADD Listeria monocytogenes bacteria | PC | Phase II clinical trial | NCT02625857 |
Active immunotherapy vaccine containing PSA to generate a T-cell response | PROSTVAC-V PROSTVAC-F GM-CSF | PROSTVAC-V/F ± GM-CSF | Asymptomatic or Minimally Symptomatic Metastatic CRPC | Phase III clinical trial | NCT01322490 |
autologous dendritic cells activated | DCVAC/PCa | VIABLE | CRPC | Phase III, IV clinical trial | NCT02107404 |
pTVG-HP + pTVG-AR is a plasmid DNA | pTVG-HP + pTVG-AR + Pembrolizumab | pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab | CRPC | Phase II clinical trial | NCT04090528 |